High-Dose Resveratrol Treatment for 2 Weeks Inhibits Intestinal and Hepatic Lipoprotein Production in Overweight/Obese Men

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Arteriosclerosis, Thrombosis and Vascular Biology

• Publication date

  2013-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/ATVBAHA.113.302342PMID 24072699
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel Role of Enteral Monosaccharides in Intestinal Lipoprotein Production in Healthy Humans

  2013cited by this paper
• High-Dose Resveratrol Supplementation in Obese Men

  2013cited by this paper
• α-Lipoic acid regulates lipid metabolism through induction of sirtuin 1 (SIRT1) and activation of AMP-activated protein kinase

  2012cited by this paper
• Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice

  2012cited by this paper
• Sirtuins mediate mammalian metabolic responses to nutrient availability

  2012cited by this paper
• Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance.

  2012cited by this paper
• Pilot study of resveratrol in older adults with impaired glucose tolerance.

  2012cited by this paper
• Response to Comment on: Marquez et al. Low-Frequency Variants in HMGA1 Are Not Associated With Type 2 Diabetes Risk. Diabetes 2012;61:524–530

  2012cited by this paper
• Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans

  2012cited by this paper
• Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases

  2012influential reference
• Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial.

  2012cited by this paper
• Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans.

  2011cited by this paper
• Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.

  2011cited by this paper
• Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients.

  2011cited by this paper
• Effects of Acute Hyperglucagonemia on Hepatic and Intestinal Lipoprotein Production and Clearance in Healthy Humans

  2011cited by this paper
• Gut-liver interaction in triglyceride-rich lipoprotein metabolism.

  2011cited by this paper
• AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice.

  2011cited by this paper
• Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis.

  2010cited by this paper
• PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure

  2009cited by this paper
• Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway.

  2009cited by this paper
• AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity

  2009cited by this paper
• Insulin Acutely Inhibits Intestinal Lipoprotein Secretion in Humans in Part by Suppressing Plasma Free Fatty Acids

  2009cited by this paper
• Short-term adaptation of postprandial lipoprotein secretion and intestinal gene expression to a high-fat diet.

  2009cited by this paper
• Reference

  2008cited by this paper
• Both Intestinal and Hepatic Lipoprotein Production Are Stimulated by an Acute Elevation of Plasma Free Fatty Acids in Humans

  2008cited by this paper
• Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase

  2008cited by this paper
• Intestinal lipoprotein overproduction in insulin-resistant states

  2008cited by this paper
• Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes Published, JLR Papers in Press, March 3, 2007.

  2007cited by this paper
• Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial.

  2006cited by this paper
• Hyperinsulinemia Is Associated With Increased Production Rate of Intestinal Apolipoprotein B-48–Containing Lipoproteins in Humans

  2006cited by this paper
• Polyphenols Stimulate AMP-Activated Protein Kinase, Lower Lipids, and Inhibit Accelerated Atherosclerosis in Diabetic LDL Receptor–Deficient Mice

  2006influential reference
• Resveratrol improves health and survival of mice on a high-calorie diet

  2006cited by this paper
• Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans.

  2004cited by this paper
• Insulin resistance and cardiovascular disease.

  2001cited by this paper
• Insulin resistance and cardiovascular disease.

  2000cited by this paper

• Phytochemicals Alter Foam Cell Formation and Macrophage Cholesterol Efflux

  2026cites this paper
• Blueberries Reduce Palm Oil‐Induced Metabolic Endotoxemia in an In Vitro Human Intestinal‐Immune Cell Model

  2025cites this paper
• Effect of Polyphenol-Rich Interventions on Gut Microbiota and Inflammatory or Oxidative Stress Markers in Adults Who Are Overweight or Obese: A Systematic Review and Meta-Analysis

  2025cites this paper
• Resveratrol: A Narrative Review Regarding Its Mechanisms in Mitigating Obesity‐Associated Metabolic Disorders

  2024cites this paper
• Dietary intake of plant polyphenols: Exploring trend in the Czech population.

  2024cites this paper
• The Gut Microbiome Affects Atherosclerosis by Regulating Reverse Cholesterol Transport

  2024cites this paper
• Postprandial glycemic and lipidemic effects of black rice anthocyanin extract fortification in foods of varying macronutrient compositions and matrices

  2023cites this paper
• The effects of phytochemicals on serum triglycerides in subjects with hypertriglyceridemia: A systematic review of randomized controlled trials

  2023cites this paper
• Resveratrol intervention attenuates chylomicron secretion via repressing intestinal FXR-induced expression of scavenger receptor SR-B1

  2023cites this paper
• Novel Role of the SIRT1 in Endocrine and Metabolic Diseases

  2023cites this paper
• The Potential to Fight Obesity with Adipogenesis Modulating Compounds

  2022cites this paper
• The Journey of Resveratrol from Vineyards to Clinics

  2022cites this paper
• The Clock‐NAD+‐Sirtuin connection in nonalcoholic fatty liver disease

  2022cites this paper
• A Review on Rhubarb-Derived Substances as Modulators of Cardiovascular Risk Factors—A Special Emphasis on Anti-Obesity Action

  2022cites this paper
• The Role of Resveratrol Administration in Human Obesity

  2021cites this paper
• The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials

  2021cites this paper
• antioxidants Hypoglycemic Effect of Resveratrol: A Systematic Review and Meta-Analysis

  2021cites this paper
• Hypoglycemic Effect of Resveratrol: A Systematic Review and Meta-Analysis

  2021cites this paper
• Mitochondrial Targeting Therapeutics: Promising Role of Natural Products in Non-alcoholic Fatty Liver Disease

  2021cites this paper
• Human Sirtuin Regulators: The “Success” Stories

  2021cites this paper
• Efficacy of Polyphenols in the Management of Dyslipidemia: A Focus on Clinical Studies

  2021cites this paper
• Prospective Pharmacological Potential of Resveratrol in Delaying Kidney Aging

  2021cites this paper
• Lipoproteins in the postprandial state

  2021cites this paper
• The role of resveratrol in diabetes and obesity associated with insulin resistance

  2021cites this paper
• Pharmacological Treatment for Aging: Are We There?

  2020cites this paper
• Usefulness of resveratrol supplementation in decreasing cardiometabolic risk factors comparing subjects with metabolic syndrome and healthy subjects with or without obesity: meta-analysis using multinational, randomised, controlled trials

  2020cites this paper
• Clinical Genetics and Genomics of Aging

  2020cites this paper
• Effects of resveratrol on mitochondrial biogenesis and physiological diseases

  2020cites this paper
• Obesity and Cardiovascular Disease: Impact of Resveratrol as a Therapeutic

  2020cites this paper
• Resveratrol: Latest Scientific Evidences of its Chemical, Biological Activities and Therapeutic Potentials

  2020cites this paper
• Regulation of apolipoprotein B by natural products and nutraceuticals: a comprehensive review.

  2020cites this paper
• Changes in immunological parameters in patients treated using direct and indirect restorations of the hard tissues of the anterior teeth in combination with an antioxidant

  2020cites this paper
• No effect of resveratrol supplementation after 6 months on insulin sensitivity in overweight adults: a randomized trial

  2020cites this paper
• Dual PPAR α / γ activation inhibits SIRT1-PGC1 α axis and causes cardiac dysfunction

  2019cites this paper
• Dual peroxisome-proliferator-activated-receptor-α/γ activation inhibits SIRT1-PGC1α axis and causes cardiac dysfunction.

  2019cites this paper
• Resveratrol, human health and winemaking perspectives

  2019cites this paper
• Resveratrol Action on Lipid Metabolism in Cancer

  2019cites this paper
• Health benefits of resveratrol: Evidence from clinical studies

  2019cites this paper
• Resveratrol ameliorates high-fat diet-induced insulin resistance and fatty acid oxidation via ATM-AMPK axis in skeletal muscle.

  2019cites this paper
• Polyphenol Health Effects on Cardiovascular and Neurodegenerative Disorders: A Review and Meta-Analysis

  2019cites this paper
• Gut microbiota and metabolomic changes associated to the beneficial effects of polyphenols on obesity

  2019cites this paper
• Investigation of human apoB48 metabolism using a new, integrated non‐steady‐state model of apoB48 and apoB100 kinetics

  2019cites this paper
• EFEITOS DA SUPLEMENTAÇÃO DE RESVERATROL SOBRE FATORES DE RISCO CARDIOVASCULAR

  2019cites this paper
• Resveratrol downregulates PCSK9 expression and attenuates steatosis through estrogen receptor α-mediated pathway in L02 cells.

  2019cites this paper
• Supplementation of grape seed and skin extract to orlistat therapy prevents high-fat diet-induced murine spleen lipotoxicity.

  2018cites this paper
• Resveratrol and Related Stilbenoids, Nutraceutical/Dietary Complements with Health-Promoting Actions: Industrial Production, Safety, and the Search for Mode of Action.

  2018cites this paper
• Resveratrol improves ex vivo mitochondrial function but does not affect insulin sensitivity or brown adipose tissue in first degree relatives of patients with type 2 diabetes

  2018cites this paper
• Recent Advances in Triacylglycerol Mobilization by the Gut.

  2018cites this paper
• Natural products for the treatment of type 2 diabetes mellitus: Pharmacology and mechanisms

  2018cites this paper
• Resveratrol

  2018cites this paper
• The Potential and Action Mechanism of Polyphenols in the Treatment of Liver Diseases

  2018cites this paper
• No effect of resveratrol on VLDL‐TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease

  2018influential citation
• Biological Activities of Resveratrol against Cancer

  2018cites this paper
• Resveratrol, Metabolic Syndrome, and Gut Microbiota

  2018cites this paper
• Health Effects of Resveratrol: Results from Human Intervention Trials

  2018cites this paper
• Mechanisms and therapeutic prospects of polyphenols as modulators of the aryl hydrocarbon receptor.

  2017cites this paper
• Traditional Chinese herbal extracts inducing autophagy as a novel approach in therapy of nonalcoholic fatty liver disease

  2017cites this paper
• Significance of Resveratrol in Clinical Management of Chronic Diseases

  2017cites this paper
• Effects of resveratrol on drug‐ and carcinogen‐metabolizing enzymes, implications for cancer prevention

  2017cites this paper
• 20. Resveratrol and metabolic syndrome in obese men – a review

  2017cites this paper
• Resveratrol: Is It Really Good for Liver Health?

  2017cites this paper
• Xenohormesis: Applying Evolutionary Principles to Contemporary Health Issues

  2017cites this paper
• Comprehensive Metabolomic Analysis in Blood, Urine, Fat, and Muscle in Men with Metabolic Syndrome: A Randomized, Placebo-Controlled Clinical Trial on the Effects of Resveratrol after Four Months’ Treatment

  2017cites this paper
• Adipose tissue NAD+ biology in obesity and insulin resistance: From mechanism to therapy.

  2017cites this paper
• Role of resveratrol in the management of insulin resistance and related conditions: Mechanism of action

  2017cites this paper
• Antioxidant effects of resveratrol in the cardiovascular system

  2017cites this paper
• Biomarkers of the metabolic syndrome: influence of selected foodstuffs, containing bioactive components

  2017cites this paper
• Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial.

  2016cites this paper
• The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials

  2016cites this paper
• Grape seed and skin extract reduces pancreas lipotoxicity, oxidative stress and inflammation in high fat diet fed rats.

  2016cites this paper
• Nucleic Acid-Targeting Pathways Promote Inflammation in Obesity-Related Insulin Resistance.

  2016influential citation
• Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic Effects

  2016cites this paper
• Challenges in Analyzing the Biological Effects of Resveratrol

  2016cites this paper
• Antidiabetic Effects of Resveratrol: The Way Forward in Its Clinical Utility

  2016cites this paper
• Targeting adipose tissue in the treatment of obesity-associated diabetes

  2016cites this paper
• Effects of dietary polyphenols on metabolic syndrome features in humans: a systematic review

  2016cites this paper
• The Effects of Resveratrol Supplementation in Overweight and Obese Humans: A Systematic Review of Randomized Trials

  2016cites this paper
• Resveratrol as Add-on Therapy in Subjects With Well-Controlled Type 2 Diabetes: A Randomized Controlled Trial

  2016cites this paper
• Resveratrol and Lifespan in Model Organisms.

  2016cites this paper
• Nucleic Acid-Targeting Pa thways Promote Inflammation in Obesity-Related Insulin Resistance Graphical

  2016cites this paper
• Are epigenetic drugs for diabetes and obesity at our door step?

  2016cites this paper
• Grape Polyphenols in the Prevention of Cardiovascular Disease

  2016cites this paper
• Resveratrol preserves the function of human platelets stored for transfusion

  2016cites this paper
• Aterofisiol® in carotid plaque evolution

  2015cites this paper
• The pharmacology of resveratrol in animals and humans.

  2015cites this paper
• Resveratrol inhibits dysfunction of dendritic cells from chronic obstructive pulmonary disease patients through promoting miR-34.

  2015cites this paper
• New Insights into the Regulation of Chylomicron Production.

  2015cites this paper
• Resveratrol and obesity: Can resveratrol relieve metabolic disturbances?

  2015cites this paper
• Novel therapeutics for type 2 diabetes: insulin resistance

  2015cites this paper
• Resveratrol Does Not Influence Metabolic Risk Markers Related to Cardiovascular Health in Overweight and Slightly Obese Subjects: A Randomized, Placebo-Controlled Crossover Trial

  2015cites this paper
• Phytochemical Compounds and Protection from Cardiovascular Diseases: A State of the Art

  2015cites this paper
• Dietary polyphenols against metabolic disorders: How far have we progressed in the understanding of the molecular mechanisms of action of these compounds?

  2015cites this paper
• Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases.

  2015cites this paper
• Resveratrol supplementation: Where are we now and where should we go?

  2015cites this paper
• The growing problem of obesity: mechanisms, consequences, and therapeutic approaches.

  2015cites this paper
• Tracking Obesity and Its Consequences From Birth to Adulthood : Does Risk Begin in the Womb ?

  2015cites this paper
• Critical review of resveratrol in xenobiotic-induced hepatotoxicity.

  2015cites this paper
• Trans-resveratrol induces a potential anti-lipogenic effect in lipopolysaccharide-stimulated enterocytes.

  2015cites this paper
• Resveratrol and diabetes: from animal to human studies.

  2015cites this paper
• Atheroprotective effects of (poly)phenols: a focus on cell cholesterol metabolism.

  2015cites this paper